Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 11 · newest first

  1. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.Journal of Clinical Oncology · 2018
  2. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II studyHaematologica · 2018
  3. Cancer research in the United States: A critical review of current status and proposal for alternative modelsCancer · 2018
  4. MYC protein expression is an important prognostic factor in acute myeloid leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2018
  5. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaCancer · 2018
  6. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemiaCancer · 2018
  7. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancersBritish Journal of Cancer · 2018
  8. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab OzogamicinAmerican Society of Clinical Oncology Educational Book · 2018
  9. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaJournal of Clinical Oncology · 2018
  10. Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndromeCancer · 2018
  11. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Cancer · 2018
  12. Improving the detection of patients with inherited predispositions to hematologic malignancies using next‐generation sequencing‐based leukemia prognostication panelsCancer · 2018
  13. The importance of greater speed in drug development for advanced malignanciesCancer Medicine · 2018
  14. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F MutationsThe American Journal of Surgical Pathology · 2018
  15. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialBlood · 2018
  16. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosisJournal of Hematology & Oncology · 2018
  17. Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemiaCancer · 2018
  18. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSClinical Cancer Research · 2018
  19. TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis.Journal of Clinical Oncology · 2018
  20. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringAmerican Journal of Hematology · 2018
  21. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATECancer · 2018
  22. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideBlood · 2018
  23. Outcomes with lower intensity therapy in TP53 -mutated acute myeloid leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2018
  24. The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatmentCA A Cancer Journal for Clinicians · 2018
  25. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasmsOncotarget · 2018
  26. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid LeukemiaActa Haematologica · 2018
  27. Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phaseCancer · 2017
  28. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosisEuropean Journal Of Haematology · 2017
  29. Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology · 2017
  30. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapyBlood Advances · 2017
  31. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive careBlood Cancer Journal · 2017
  32. Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid LeukemiaBlood · 2017
  33. Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AMLBlood · 2017
  34. Outcomes By Treatment Setting and Genomic Profile in Patients with AML on Cladribine, Idarubicin, and CytarabineBlood · 2017
  35. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaCancer · 2017
  36. Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primatesView · 2017
  37. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitorsCurrent Opinion in Hematology · 2017
  38. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionAmerican Journal of Hematology · 2017
  39. The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabBritish Journal of Haematology · 2017
  40. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasmsAmerican Journal of Hematology · 2017
  41. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)Experimental Hematology and Oncology · 2017
  42. Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activitiesOncotarget · 2017
  43. Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapyCancer · 2017
  44. Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphomaAmerican Journal of Hematology · 2017
  45. High-throughput single-cell DNA sequencing of AML tumors with droplet microfluidics2017
  46. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitorsAmerican Journal of Hematology · 2017
  47. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adultsAmerican Journal of Hematology · 2017
  48. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingLeukemia & lymphoma/Leukemia and lymphoma · 2017
  49. PET-CT in AML-related hemophagocytic lymphohistiocytosisLeukemia & lymphoma/Leukemia and lymphoma · 2017
  50. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemiaJournal of Cutaneous Pathology · 2017